HFA Premium Access

Empagliflozin in heart failure with preserved ejection fraction: decoding its molecular mechanism of action using artificial intelligence

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Congress Presentation

About the speaker

Doctor Oriol Iborra Egea

Health Science Research Institute Germans Trias i Pujol (IGTP), Badalona (Spain)
2 presentations
0 follower

9 more presentations in this session

Real world analysis of outcomes of remote pulmonary artery hemodynamic monitoring in overweight and obese patients with heart failure

Speaker: Doctor M. Oberoi (Sioux Falls, US)


Multicenter nationwide study of the prevalence of ATTR-CM in HFpEF in Spain. Intermediate results from national PRACTICA study.

Speaker: Doctor J. Garcia-Pinilla (Malaga, ES)


HDAC6 inhibition improves diastolic function in a mouse model of heart failure with preserved ejection fraction

Speaker: Mr J. Yang (South San Francisco, US)


Pulmonary hypertension in heart failure with preserved ejection fraction: the TOPCAT Americas and PARAGON-HF studies

Speaker: Doctor K. Jering (Boston, US)


Changes in natriuretic peptide and effects of vericiguat in worsening heart failure with reduced ejection fraction: Insights from VICTORIA (VerICiguaT Global Study in Subjects with HFrEF)

Speaker: Doctor J. Ezekowitz (Edmonton, CA)


Access the full session

Chronic Heart Failure - Pathophysiology and Mechanisms 1

Speakers: Doctor O. Iborra Egea, Doctor M. Oberoi, Doctor J. Garcia-Pinilla, Mr J. Yang, Doctor K. Jering...

About the event


Heart Failure 2021

29 June - 1 July 2021

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb